Targeting the NF-κB signaling pathway of tumor-associated macrophages, affecting the level of p62 to activate the autophagy, enabled the tumor-center T cells to restore their sensitivity to anti-PD-L1 therapy [18,19]. The gene discussed is NFKB1; the disease is neoplasm.